17471

Differential Responses to Acarbose Between Obese and Non-obese Patients with Type 2 Diabetes Mellitus

63

69

7

To investigate the responses in terms of body weight, glycemic control, metabolic control, and the side effects to acarbose add-on therapy in obese and non-obese type 2 diabetes patients with inadequately controlled by sulfonylureas and metformin. Materials and Methods: Forty obese (BMI > 27) and 80 sex- and age-matched non-obese patients with type 2 diabetes mellitus were enrolled in this 3-month, open-label, case-controlled trial for acarbose add-on therapy. Totally 111 (73 nonobese and 38 obese) patients completed 3-month acarbose add-on therapy. This study adopted a 2center open-label parallel group design. After a 4-week run-in period, acarbose was added (titrated up to 100 mg t.i.d.) to the current sulfonylureas and metformin combined therapy of subjects. Both obese patients (9.3±1.3% vs, 8.3±1.6%, p

1201393